Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 6361 AL 6375

Modulation of Cortical and Hippocampal Functional MRI Connectivity Following Transcranial Alternating Current Stimulation in Mild Alzheimer Disease

Wang T, Yan S, Shan Y, Xue H, Xing Y, Bi S, Chen Z, Xi H, Qi Z, Tang Y, Lu J.

Radiology. 2025 Jun;315(3):e241463. doi: 10.1148/radiol.241463.

A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease

Cury RM, da Silva T, Cezar-Dos-Santos F, Fakih YRC, Narvaez KAR, Gouvea MC, Espínola C, Ferreira CF, de Castro WAC, Pamplona FA, Silva EGD, Bicca MA, Nascimento FP.

J Alzheimers Dis. 2025 Dec;108(4):1602-1613. doi: 10.1177/13872877251389608. Epub 2025 Oct 29.

Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial

Koch G, Casula EP, Bonnì S, Borghi I, Assogna M, Di Lorenzo F, Esposito R, Maiella M, D'Acunto A, Ferraresi M, Mencarelli L, Pezzopane V, Motta C, Santarnecchi E, Bozzali M, Martorana A.

Alzheimers Res Ther. 2025 Apr 2;17(1):69. doi: 10.1186/s13195-025-01709-7.

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, Hu H, Lu M, Oru E, Ardayfio PA, Hoban DB, Collins EC, Brooks DA, Sims JR.

Alzheimers Dement. 2025 May;21(5):e70293. doi: 10.1002/alz.70293.

Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3

Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, Reiman EM, Tariot PN, Alexander R, Langbaum JB, Sims JR.

Alzheimers Dement. 2025 Sep;21(9):e70662. doi: 10.1002/alz.70662.

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, Shcherbinin S, Andersen SW, Hauck PM, Engle SE, Brooks DA, Collins EC, Fox NC, Greenberg SM, Salloway S, Mintun MA, Sims JR.

Alzheimers Dement. 2025 Apr;21(4):e70062. doi: 10.1002/alz.70062.

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, Tronchin G, Sato S, Raket LL, Andersen SW, Sapin C, Paget MA, Gueorguieva I, Ardayfio P, Khanna R, Brooks DA, Matthews BR, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative.

J Prev Alzheimers Dis. 2026 Feb;13(2):100446. doi: 10.1016/j.tjpad.2025.100446. Epub 2025 Dec 1.

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials

Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battioui C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR.

JAMA Neurol. 2025 May 1;82(5):461-469. doi: 10.1001/jamaneurol.2025.0065.

Determination of Factors Associated With Urinary Incontinence in Older Individuals With Alzheimer's Disease: A Cross-Sectional Study

Özden F, Özkeskin M, Benzer Z, Uysal İ, Işık Eİ, Başer M.

Psychogeriatrics. 2025 Jul;25(4):e70058. doi: 10.1111/psyg.70058.

Technology readiness among UK-based cognitively unaffected older adults during the COVID-19 pandemic: potential implications for decentralised alzheimer's disease prevention trials

Taylor S, Dunn L, Udeh-Momoh C, Abbott K, Giannakopoulou P, Middleton L, Robinson O, Kalsi J, Kafetsouli D, Ford J.

BMC Geriatr. 2025 Jul 30;25(1):563. doi: 10.1186/s12877-025-06158-3.

[Observational study on the coincidence of Alzheimer's disease and idiopathic normal pressure hydrocephalus: analysis of coincidence, the influence on response to cerebrospinal fluid drainage and cerebrovascular copathology]

Beeke M, Sauer C, Petzold J, Schneider S, Frenzen K, Donix M, Reiß G, Brandt M, Haußmann R.

Nervenarzt. 2025 Dec;96(7):686-695. doi: 10.1007/s00115-025-01808-8. Epub 2025 Feb 27.

Lucid episodes among people with Alzheimer's disease and related dementias and their impact on family caregiver stress and grief (LEAD): protocol for a longitudinal observational study

Griffin JM, Bangerter LR, Kim K, Liu Y, Batthyány A, Birkeland RW, Frangiosa TL, Nosheny RL, Gaugler J, Lapid MI.

BMJ Open. 2025 Jul 10;15(7):e098182. doi: 10.1136/bmjopen-2024-098182.

Community-based participatory research on Alzheimer's disease and related dementias among Tibetan Buddhist monks in South India: The Lifestyle Assessment and Monastic Aging Study (LAMAS)

Namdul T, MacLehose R, Pasang T, Madesclaire O, Gyatso G, Henderson A, Buchwald D.

Alzheimers Dement. 2025 Nov;21(11):e70834. doi: 10.1002/alz.70834.

Variation in Phenotype Definitions in Observational Clinical Research: A Review of Three Conditions

Shoaibi A, Ostropolets A, Weaver J, Rao GA, Golozar A, Swerdel J, Huser V, Adam A, Alshammari T, Anikpezie N, Baumgartner WA Jr, Brand M, Fan R, Kanter AS, Kern D, Melisa S, Minty E, Mo J, Oluwalade B, Schilling LM, Spence H, Stocking JC, Zhang L, Ryan P.

AMIA Annu Symp Proc. 2025 May 22;2024:1021-1029. eCollection 2024.

Validity of gold-standard clinical outcome assessments in U.S. Latinx-Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review

Monserratt LH, Morales JA, Mohammed A, Ovalle-Eliseo S, Islas-Huerta G, Perez LA, Díaz-Santos M.

Alzheimers Dement. 2025 Dec;21(12):e70918. doi: 10.1002/alz.70918.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias